查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1970862

腕隧道症候群市場－全球產業規模、佔有率、趨勢、機會、預測：按診斷、治療、地區和競爭對手分類，2021-2031年

Carpal Tunnel Syndrome Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnosis, By Treatment, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球腕隧道症候群市場預計將從 2025 年的 9.8123 億美元成長到 2031 年的 12.1671 億美元，複合年成長率為 3.65%。

此市場領域涵蓋用於診斷和治療腕部正中神經壓迫的手術器材、藥品和醫療設備。推動這一成長的主要因素包括：數位化和久坐生活方式導致的重複性勞損日益普遍，以及全球人口老化加劇，老年人更容易患上肌肉骨骼疾病。此外，肥胖和糖尿病等合併症發病率的上升也持續增加需要臨床介入的患者數量。英國健康與安全部門的數據顯示，2024年英國職業傷害與殘障福利計畫將正式確認105例腕隧道症候群新病例，這進一步印證了該疾病的職業因素依然存在。

市場概覽
預測期 2027-2031
市場規模：2025年 9.8123億美元
市場規模：2031年 1,216,710,000 美元
複合年成長率：2026-2031年 3.65%
成長最快的細分市場 製藥
最大的市場 北美洲

儘管存在這些有利的成長要素，但由於手術切除費用高成本以及術後併發症風險，市場仍面臨許多障礙。發展中地區的經濟限制，加上其他非侵入性治療方法的出現，往往導致患者延後或避免接受更複雜的治療。這些經濟限制和保守的治療方法選擇有效地限制了市場的整體擴張。

市場促進因素

微創手術技術，特別是超音波導引腕隧道鬆解術的日益普及，是推動市場成長的主要動力。與傳統開放性手術相比，這些先進的手術切口更小，恢復時間更短，提高了患者的接受度，並促進了以診所為基礎、更經濟高效的治療模式的轉變。這項技術進步既滿足了門診治療的需求，也減輕了住院帶來的經濟負擔。根據Sonex Health於2024年6月發布的ECRI積極評估報告，醫生已開展了超過31,000例超音波引導腕管松解術，顯示該技術在臨床實踐中得到了迅速應用。手術量的增加反映了市場正朝著以設備為中心、最大限度減少醫療資源消耗的解決方案轉變。

同時，代謝性疾病及其相關併發症（例如類風濕性關節炎）的發生率不斷上升，導致需要治療的患者群體日益擴大。全身性發炎性疾病常引起正中神經受壓，對診斷和治療管理產生了持續的需求。美國風濕病學會於2024年11月發表的一項題為《腕隧道症候群：類風濕性關節炎早期未被識別的特徵》的研究證實，類風濕性關節炎患者的腕管症候群患病率比非患者高1.5倍，凸顯了慢性疾病與整形外科神經病變之間的關聯。這種關聯加劇了疾病的整體負擔。 2024年12月，美國國立衛生研究院（NIH）估計，全球腕隧道症候群的盛行率已達總合%，顯示治療市場潛力巨大。

市場挑戰

手術減壓的高昂費用以及治療帶來的沉重經濟負擔是全球腕隧道症候群市場成長的主要障礙。這些經濟障礙直接限制了患者獲得先進手術介入的機會，尤其是在醫療保險報銷有限或自付費用過過高的地區。隨著醫療保健總成本的上升，醫療服務提供者和保險公司更有獎勵推遲侵入性手術，優先考慮保守的非手術治療。這降低了對手術器械和設備的即時需求。這種成本敏感性迫使支付方實施更嚴格的合格標準和更長的等待期，最終導致手術數量減少。

此外，高昂的成本造成了複雜的報銷環境，阻礙了市場推廣。根據美國國家安全委員會統計，2024年腕隧道症候群的平均勞工賠償金額約為34,000美元，這反映了該疾病帶來的巨大經濟負擔。這些飆升的成本限制了外科治療方案生產商的商機，並阻礙了先進治療方法的廣泛應用。

市場趨勢

將人工智慧 (AI) 和機器學習應用於診斷領域，顯著提升了正中神經病變的辨識率。如今，演算法能夠輔助臨床醫生自動分割超音波影像中的神經邊界，最大限度地減少觀察者間的差異，並提高診斷的準確性。這項技術突破使得早期發現傳統人工評估中常被忽略的細微形態學變化成為可能，從而降低了複雜病例的誤診率。根據 ReachMD 於 2025 年 3 月發表的題為「革新腕隧道症候群診斷」的報導，近期使用人工智慧增強超音波系統的研究實現了 0.96 的診斷準確率，顯著優於傳統的影像分析方法，並簡化了臨床工作流程。

同時，再生醫學和生物療法的日益普及正在改變保守治療的格局。與僅能暫時緩解症狀的皮質類固醇不同，富血小板血漿（PRP）等骨生物製藥透過提供生長因子，著重於修復神經組織和恢復生理功能。這種方法不僅能消除炎症，還能修復潛在的神經損傷，為患者提供了一種無需手術減壓的持久治療方案。根據美國神經病學會2025年4月發表的論文《富血小板血漿與類固醇注射療效比較》，PRP治療組的症狀嚴重程度評分為-1.31，顯著低於皮質類固醇治療組的-0.79，這支持了生物干預的治療效果。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球腕隧道症候群市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依類型診斷（電生理檢查、影像檢查）
    • 治療方法（藥物治療、綜合治療、手術）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美腕隧道症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲腕隧道症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區腕隧道症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲腕隧道症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲腕隧道症候群市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球腕隧道症候群市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • Stryker Corporation
  • Smith & Nephew Plc
  • CONMED Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 27654

The Global Carpal Tunnel Syndrome Market is projected to expand from USD 981.23 Million in 2025 to USD 1216.71 Million by 2031, reflecting a CAGR of 3.65%. This market sector encompasses surgical instruments, pharmaceuticals, and medical devices used to diagnose and manage median nerve compression within the wrist. Key factors driving this growth include the rising prevalence of repetitive strain injuries attributed to increased digitalization and sedentary lifestyles, alongside an aging global population susceptible to musculoskeletal disorders. Additionally, the growing incidence of comorbidities such as obesity and diabetes continues to increase the volume of patients requiring clinical intervention. Data from the Health and Safety Executive indicates that in 2024, 105 new cases of Carpal Tunnel Syndrome were officially assessed under the Industrial Injuries Disablement Benefit scheme in Great Britain, underscoring the persistent occupational nature of the condition.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 981.23 MIllion
Market Size 2031USD 1216.71 MIllion
CAGR 2026-20313.65%
Fastest Growing SegmentMedication
Largest MarketNorth America

Despite these favorable growth drivers, the market encounters significant obstacles due to the high costs of surgical release procedures and the risk of post-operative complications. Financial limitations in developing regions, combined with the availability of alternative non-invasive therapies, often lead patients to delay or avoid advanced medical treatments. These economic constraints and the preference for conservative care options effectively restrain the overall expansion of the market.

Market Driver

The rising adoption of minimally invasive surgical techniques, specifically ultrasound-guided carpal tunnel release, acts as a major catalyst for market growth. These advanced procedures offer smaller incisions and reduced recovery times compared to traditional open surgery, encouraging patient acceptance and facilitating a shift toward cost-effective office-based settings. This technological evolution meets the demand for outpatient care while alleviating the economic burden associated with hospital stays. According to a June 2024 announcement by Sonex Health regarding an ECRI favorable rating, physicians have performed more than 31,000 ultrasound-guided carpal tunnel release procedures, highlighting the rapid clinical integration of this technology. This increase in procedural volume reflects the market's pivot toward device-centric solutions that minimize healthcare resource utilization.

Concurrently, the escalating incidence of associated comorbidities, including metabolic disorders and rheumatoid arthritis, continues to broaden the patient base requiring intervention. Systemic inflammatory conditions frequently trigger median nerve compression, creating sustained demand for diagnostic and therapeutic management. A study published by the American College of Rheumatology in November 2024, titled 'Carpal Tunnel Syndrome Is an Early Unrecognized Feature of Rheumatoid Arthritis,' identified the condition as being 1.5 times more common in individuals with rheumatoid arthritis than in those without, emphasizing the link between chronic disease and orthopedic neuropathy. This correlation amplifies the overall disease burden, with the National Institutes of Health estimating in December 2024 that the combined global prevalence of Carpal Tunnel Syndrome has reached 14.4%, indicating a substantial market for therapeutic providers.

Market Challenge

The substantial expense associated with surgical release procedures and the broader economic burden of treatment constitute a primary impediment to the growth of the Global Carpal Tunnel Syndrome Market. These financial barriers directly limit patient access to advanced surgical interventions, particularly in regions where healthcare reimbursement is restricted or out-of-pocket costs are prohibitive. As the total cost of care increases, healthcare providers and insurers are increasingly incentivized to delay invasive procedures in favor of conservative, non-surgical alternatives, thereby reducing the immediate demand for surgical devices and instrumentation. This sensitivity to cost compels payers to enforce stricter eligibility criteria or prolonged wait times, effectively throttling the volume of surgeries performed.

Furthermore, the high costs create a difficult reimbursement environment that suppresses market adoption rates. According to the National Safety Council, the average workers' compensation settlement for a Carpal Tunnel Syndrome claim was approximately $34,000 in 2024, reflecting the considerable financial liability associated with the condition. Such elevated costs restrict revenue opportunities for manufacturers of surgical solutions and hamper the widespread adoption of advanced treatment modalities.

Market Trends

The integration of Artificial Intelligence and Machine Learning into diagnostics is significantly advancing the identification of median nerve pathology. Algorithms now assist clinicians by automating the segmentation of nerve boundaries in ultrasound imagery, which minimizes inter-observer variability and boosts diagnostic confidence. This technological leap enables earlier detection of subtle morphological changes that traditional manual assessments might miss, reducing misdiagnosis rates in complex cases. According to a ReachMD article from March 2025 titled 'Revolutionizing Carpal Tunnel Syndrome Diagnosis,' recent studies utilizing AI-enhanced ultrasound systems demonstrated a diagnostic accuracy of 0.96, significantly outperforming conventional imaging interpretation methods and streamlining clinical workflows.

Simultaneously, the rising utilization of regenerative medicine and biologic therapies is shifting the landscape of conservative management. Unlike corticosteroids, which offer temporary symptom relief, orthobiologics such as platelet-rich plasma (PRP) focus on repairing neural tissue and restoring physiological function through growth factor delivery. This approach targets the underlying nerve damage rather than merely suppressing inflammation, offering patients a durable alternative to surgical decompression. As reported by the American Academy of Neurology in an April 2025 abstract titled 'Efficacy of Platelet-rich Plasma Versus Steroid Injections,' patients treated with PRP exhibited a superior long-term reduction in symptom severity scores of -1.31 compared to -0.79 for those receiving corticosteroids, highlighting the therapeutic efficacy of biologic interventions.

Key Market Players

  • GlaxoSmithKline Plc
  • Pfizer Inc.
  • Johnson & Johnson
  • Novartis AG
  • Stryker Corporation
  • Smith & Nephew Plc
  • CONMED Corporation
  • Teva Pharmaceutical Industries Ltd.
  • Bristol-Myers Squibb Company
  • AbbVie Inc.

Report Scope

In this report, the Global Carpal Tunnel Syndrome Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Carpal Tunnel Syndrome Market, By Diagnosis

  • Electrophysiological Tests
  • Imaging Tests

Carpal Tunnel Syndrome Market, By Treatment

  • Medication
  • Integrative Therapy
  • Surgery

Carpal Tunnel Syndrome Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Carpal Tunnel Syndrome Market.

Available Customizations:

Global Carpal Tunnel Syndrome Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Carpal Tunnel Syndrome Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Diagnosis (Electrophysiological Tests, Imaging Tests)
    • 5.2.2. By Treatment (Medication, Integrative Therapy, Surgery)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Carpal Tunnel Syndrome Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Diagnosis
    • 6.2.2. By Treatment
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Carpal Tunnel Syndrome Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Diagnosis
        • 6.3.1.2.2. By Treatment
    • 6.3.2. Canada Carpal Tunnel Syndrome Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Diagnosis
        • 6.3.2.2.2. By Treatment
    • 6.3.3. Mexico Carpal Tunnel Syndrome Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Diagnosis
        • 6.3.3.2.2. By Treatment

7. Europe Carpal Tunnel Syndrome Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Diagnosis
    • 7.2.2. By Treatment
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Carpal Tunnel Syndrome Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Diagnosis
        • 7.3.1.2.2. By Treatment
    • 7.3.2. France Carpal Tunnel Syndrome Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Diagnosis
        • 7.3.2.2.2. By Treatment
    • 7.3.3. United Kingdom Carpal Tunnel Syndrome Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Diagnosis
        • 7.3.3.2.2. By Treatment
    • 7.3.4. Italy Carpal Tunnel Syndrome Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Diagnosis
        • 7.3.4.2.2. By Treatment
    • 7.3.5. Spain Carpal Tunnel Syndrome Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Diagnosis
        • 7.3.5.2.2. By Treatment

8. Asia Pacific Carpal Tunnel Syndrome Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Diagnosis
    • 8.2.2. By Treatment
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Carpal Tunnel Syndrome Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Diagnosis
        • 8.3.1.2.2. By Treatment
    • 8.3.2. India Carpal Tunnel Syndrome Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Diagnosis
        • 8.3.2.2.2. By Treatment
    • 8.3.3. Japan Carpal Tunnel Syndrome Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Diagnosis
        • 8.3.3.2.2. By Treatment
    • 8.3.4. South Korea Carpal Tunnel Syndrome Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Diagnosis
        • 8.3.4.2.2. By Treatment
    • 8.3.5. Australia Carpal Tunnel Syndrome Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Diagnosis
        • 8.3.5.2.2. By Treatment

9. Middle East & Africa Carpal Tunnel Syndrome Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Diagnosis
    • 9.2.2. By Treatment
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Carpal Tunnel Syndrome Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Diagnosis
        • 9.3.1.2.2. By Treatment
    • 9.3.2. UAE Carpal Tunnel Syndrome Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Diagnosis
        • 9.3.2.2.2. By Treatment
    • 9.3.3. South Africa Carpal Tunnel Syndrome Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Diagnosis
        • 9.3.3.2.2. By Treatment

10. South America Carpal Tunnel Syndrome Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Diagnosis
    • 10.2.2. By Treatment
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Carpal Tunnel Syndrome Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Diagnosis
        • 10.3.1.2.2. By Treatment
    • 10.3.2. Colombia Carpal Tunnel Syndrome Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Diagnosis
        • 10.3.2.2.2. By Treatment
    • 10.3.3. Argentina Carpal Tunnel Syndrome Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Diagnosis
        • 10.3.3.2.2. By Treatment

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Carpal Tunnel Syndrome Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. GlaxoSmithKline Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Pfizer Inc.
  • 15.3. Johnson & Johnson
  • 15.4. Novartis AG
  • 15.5. Stryker Corporation
  • 15.6. Smith & Nephew Plc
  • 15.7. CONMED Corporation
  • 15.8. Teva Pharmaceutical Industries Ltd.
  • 15.9. Bristol-Myers Squibb Company
  • 15.10. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer